Follow us on Twitter
twitter icon@FreshPatents


Codon patents

      

This page is updated frequently with new Codon-related patent applications.




 Method for suppressing cell growth patent thumbnailMethod for suppressing cell growth
Disclosed is a method for suppressing the growth of a target cell, which is not limited in the type of a target cell and the type of a protein to be expressed in the target cell and needs not any preparatory experiment for determining a codon to be contained in a protein to be expressed in a target cell. Specifically disclosed is a method for suppressing the growth of a target cell, which comprises the steps of: incorporating dna containing a region encoding a protein into the target cell, and allowing a protein encoded by the dna to be expressed in the target cell into which the dna has been incorporated.
Japan Agency For Marine-earth Science And Technology


 Attenuated viruses useful for vaccines patent thumbnailAttenuated viruses useful for vaccines
This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject.
The Research Foundation For The State University Of New York


 Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid patent thumbnailPharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
Provided herein are pharmaceutical compositions, which comprise a 1,2,4-oxadiazole benzoic acid or a pharmaceutically acceptable salt thereof. Further provided herein are certain pharmaceutically acceptable salts of a 1,2,4-oxadiazole benzoic acid and methods for making the same.
Ptc Therapeutics, Inc.


 Chinese medicine prescription capable of treating lung adenocarcinoma patent thumbnailChinese medicine prescription capable of treating lung adenocarcinoma
A chinese medicine prescription capable of treating lung adenocarcinoma is composed of polygala tenuifolia willd, atractylodes macrocephala, angelica sinensis, poria pararadicis, astragalus membranaceus, ziziphus jujaba mill.var.spinosa, codonopsis pilosula, costustoot, radix glycyrrhizae preparata and fresh ginger, and a pharmaceutical residue is filtered and obtained after a water quenching procedure of the aforementioned herbs to provide a water-quenched medicine soup, and a pharmaceutical residue is filtered and obtained after processing the water-quenched pharmaceutical residue by a liquor quenching procedure to obtain a liquor-quenched medicine soup; and the water-quenched medicine soup and the liquor-quenched medicine soup are mixed. The prescription is capable of triggering cell autophagy and reducing cell growth, expansion and metastasis, so as to achieve the effect of lung adenocarcinoma treatment..

 Phage display library patent thumbnailPhage display library
A library of replicating entities, each entity comprises a recombinant vector comprising a randomized nucleic acid sequence, having the reading frame structure [nxx]n [coraa] [nxx]m [nzz]o, or [nzz]o [nxx]m [coraa] [nxx]n. Each nxx is independently a codon encoding for any amino acid except cysteine, coraa is a codon encoding for cysteine or at least one other amino acid, each nzz is independently a codon encoding for any amino acid, and n is an integer from 0 to 40, m is an integer from 1 to 20, o is an integer from 1 to 40, and at least 20 percent of coraa encode for cysteine.
Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.


 Compositions for the inactivation of virus replication and methods of making and using the same patent thumbnailCompositions for the inactivation of virus replication and methods of making and using the same
Provided herein are recombinant constructs, vectors and expression cassettes including a first promoter which is suitably a trna promoter operably connected to a first polynucleotide encoding a first single guide rna and a second promoter operably connected to a second polynucleotide encoding a cas9 polypeptide. The first single guide rna includes a first portion complementary to a strand of a target sequence of a dna virus and a second portion capable of interacting with the cas9 polypeptide.
Emory University


 Pharmaceutical compositions for treating or preventing pain patent thumbnailPharmaceutical compositions for treating or preventing pain
Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat or prevent pain in a subject, and to reduce or prevent an adverse effect associated with the analgesics.. .
Locl Pharma, Inc.


 Treating pain in patients with hepatic impairment patent thumbnailTreating pain in patients with hepatic impairment
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited


 Compositions and methods for making selenocysteine containing polypeptides patent thumbnailCompositions and methods for making selenocysteine containing polypeptides
Non-naturally occurring trnasec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring trnasec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mrna without the requirement of an secis element.
Yale University


 Codon-optimized gene for mutated shrimp luciferase and  use thereof patent thumbnailCodon-optimized gene for mutated shrimp luciferase and use thereof
There has been a demand for a codon-optimized gene for the mutated catalytic domain of oplophorus luciferase, which is capable of efficiently expressing a protein both in a cultured animal cell and escherichia coli. There has also been a demand for a substrate coelenterazine analogue showing a higher activity than that of native 19 kda protein.
Jnc Corporation


Treatment of hyperbilirubinemia

The invention relates to a nucleic acid sequence useful in the treatment of hyperbilirubinemia, in particular in the treatment of crigler-najjar syndrome. More particularly, the nucleic acid sequence of the present invention is a codon-optimized ugt1a1 coding sequence..
International Center For Genetic Engineering And Biotechnology

Process for reducing contaminating michael acceptor levels in oxycodone and other compositions

The present invention relates to processes for removal of michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove michael acceptors and the resulting thiol-michael adducts. Certain embodiments of the present invention enable quantification and/or removal of michael acceptors and/or michael acceptor precursors..
Controlled Chemicals, Inc.

Process for improved oxycodone synthesis

Processes for preparing oxycodone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxycodeinone salt in the presence of trifluoroacetic acid and/or a glycol..
Rhodes Technologies

Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Design of mrna sequences to control co-translational folding of proteins

This invention relates to optimized heterologous production of properly folded and functional proteins. The present invention provides systems and methods involving determination of the optimal mrna sequence, based on the underlying rates at which codons are translated and folding kinetic of nascent-protein, that maximizes co-translational protein folding of domains in order to maximize the proper folding and quality of the protein produced.
The Penn State Research Foundation

Formulations of nonopioid and confined opioid analgesics

The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse.
Abbvie Inc.

Compositions and methods for making selenocysteine containing polypeptides

Non-naturally occurring trnasec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring trnasec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mrna without the requirement of an secis element.
Yale University

Methods for efficient, expansive, user-defined dna mutagenesis

The presently disclosed subject matter provides methods for the creation of one or more user-defined mutations that can be located anywhere in a target sequence, such as in a gene. These mutations can comprise single mutations, multiple mutations, or a comprehensive codon mutagenesis library, in which all possible single codon substitutions in a gene are created.
The Johns Hopkins University

Heterologous expression of fungal cellobiohydrolase 2 genes in yeast

The present invention provides for heterologous expression of polypeptides encoded by wild-type and codon-optimized cbh2 genes from the organisms cochliobolus heterostrophus, gibberella zeae, irpex lacteus, volvariella volvacea, and piromyces sp. In host cells, such as the yeast saccharomyces cerevisiae.
Stellenbosch University

Ptd-smad7 therapeutics

The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described.
The Regents Of The University Of Colorado, A Body Corporate

Adeno-associated virus vectors for treatment of glycogen storage disease

The present disclosure describes improved adeno-associated virus (aav) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type ia (gsd-ia). Described are recombinant nucleic acid molecules, vectors and recombinant aav that include a g6pc promoter/enhancer, a synthetic intron, a g6pc coding sequence (such as a wild-type or codon-optimized g6pc coding sequence), and stuffer nucleic acid sequence situated between the g6pc promoter/enhancer and the intron, as well as between the intron and the g6pc coding sequence.
University Of Florida Research Foundation, Incorporated

Method of increasing biomass and lipid content in a micro-organism and a genetically modified micro-organism exhibiting enhanced autophagy

According to an embodiment of the invention, there is provided a method of increasing biomass and lipid content in a micro-organism comprising cloning in a vector an exogenous gene sequence selected from the group comprising atg1 gene, atg6 gene, and atg8 gene sequence wherein the sequence is codon optimized for said micro-organism, for inducing autophagy; introducing the vector containing the gene into the genome of the micro-organism to yield a genetically modified micro-organism; and growing the genetically modified micro-organism in suitable medium. According to another embodiment of the invention there is provided a method of increasing biomass and lipid content in a micro-organism exposed to stress, comprising treating the microorganism with an autophagy inducing agent..
Reliance Industries Limited

Method for producing polyunsaturated fatty acids

The invention relates to a method for producing eicosapentanoic acid, docosapentanoic acid and/or docohexanoic acid in transgenic plants. According to said method, the plant is provided with at least one nucleic acid sequence coding for a polypetide with a Δ6 desaturase activity, at least one nucleic acid sequence coding for a polypeptide with a Δ6 elongase activity, at least one nucleic acid sequence coding for a polypeptide with a Δ5 desaturase activity, and at least one nucleic acid sequence coding for a polypeptide with a Δ5 elongase activity, the nucleic acid sequence coding for a polypeptide with a Δ5 elongase activity being modified in relation to the nucleic acid sequence in the organism from which the sequence originates, such that it is adapted to the codon use in at least one type of plant.
Basf Plant Science Gmbh

Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Effect of ppegid1c on vegetative growth of fruit trees

The genetic basis for a recessive dwarf trait (dw) in peach (prunus persica) was determined. Using a sequencing-based bulk-segregant mapping strategy, dw was positioned on the distal end of peach chromosome 6.
The United States Of America, As Represented By The Secretary Of Agriculture

Live-attenuated virus and methods of production and use

Presented herein are live-attenuated viruses and methods of generating thereof from a parental virus through a plurality of nucleotide substitutions in the viral genome. The nucleotide substitutions result in a change in codon usage bias within codons of one or more protein encoding sequences and no change in amino acid sequences of the proteins.
The University Of Hong Kong

Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Treating pain in patients with hepatic impairment

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited

Sin nombre virus full-length m segment-based dna vaccines

The invention contemplates a new synthetic, codon-optimized sin nombre virus (snv) full-length m gene open reading frame (orf) that encodes a unique consensus amino acid sequence. The snv orf was cloned into a plasmid to form the first stable recombinant snv full-length m gene that elicits neutralizing antibodies.
The United States Of America, As Rep. By The Sec'y Of The Army, For U.s. Army Medical Research Insti

Pharmaceutical compositions for treating or preventing pain

Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat or prevent pain in a subject, and to reduce or prevent an adverse effect associated with the analgesics.. .
Locl Pharma, Inc.

Methods and compositions for determining virus susceptibility to integrase inhibitors

Methods and compositions for the efficient and accurate determination of hiv susceptibility to an integrase inhibitor and/or hiv replication capacity are provided. In certain aspects, the methods involve detecting in a biological sample a nucleic acid encoding an hiv integrase that comprises a primary mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (r) or cysteine (c), and wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the hiv has a decreased susceptibility to an integrase inhibitor or altered replication capacity relative to a reference hiv.
Laboratory Corporation Of America Holdings

Histidine engineered light chain antibodies and genetically modified non-human animals for generating same

A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
Regeneron Pharmaceuticals, Inc.

Method for detection of a nucleic acid target sequence

Disclosed is a method of facilitating detection of a nucleic acid target sequence. The method may include obtaining a toehold-mediated dna strand displacement apparatus comprising a portion complementary to the nucleic acid target sequence.
Totemid Inc.

Synthetic genes

The invention provides synthetic nucleic acid sequences encoding proteins of interest that are particularly adapted to express well in plants. The claimed synthetic sequences utilize plant-optimized codons roughly in the same frequency at which they are utilized, on average, in genes naturally occurring in the plant species.
Dow Agrosciences Llc

Codon-optimized gene for mutated shrimp luciferase and use thereof

There has been a demand for a codon-optimized gene for the mutated catalytic domain of oplophorus luciferase, which is capable of efficiently expressing a protein both in a cultured animal cell and escherichia coli. There has also been a demand for a substrate coelenterazine analogue showing a higher activity than that of native 19 kda protein.
Jnc Corporation

Production charged non-protein amino acid-containing peptide

The present invention provides a method of producing a peptide containing a charged non-proteinogenic amino acid. It includes a step of expressing a peptide in a cell-free translation system including (i) at least one trna to which a non-proteinogenic amino acid having a protecting-group-introduced charged group has been bound and (ii) a nucleic acid that encodes the peptide and contains at least one codon corresponding to an anticodon of the trna; and a step of removing the protecting group of the non-proteinogenic amino acid residue contained in the peptide..

Sustained release monoeximic formulations of opioid and nonopioid analgesics

The present invention relates to monoeximic solid dosage forms for administering pharmaceutical agents, particularly hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment.. .
Abbvie Inc.

Poxvirus expression system

There is provided a method for inserting a nucleic acid sequence that encodes a foreign peptide into a poxvirus genome, said method comprising: identifying in the poxvirus genome a poxvirus open reading frame wherein said open reading frame is characterised by an initial atg start codon and wherein expression of said open reading frame is driven by an operably-linked poxvirus promoter located upstream of the open reading frame and wherein expression of said open reading frame provides a peptide that is non-essential to viability of the poxvirus; and inserting the nucleic acid sequence that encodes the foreign peptide at a position downstream of the poxvirus promoter; wherein following said insertion, (i) the nucleic acid that encodes the foreign peptide is operably-linked to the poxvirus promoter and expression of said nucleic acid is driven by said poxvirus promoter; and (ii) translation of the foreign peptide is initiated at an atg start codon located at the same position as the atg start codon of the poxvirus open reading frame. Also provided are a poxvirus vector and corresponding uses of the poxvirus vector in medicine..
Isis Innovation Limited



Codon topics:
  • Hydrocodone
  • Nucleic Acid
  • Acetaminophen
  • Carboxylic Acid
  • Benzoic Acid
  • Genetically
  • Recombinant
  • Amino Acid
  • Nucleotide
  • Reverse Transcriptase Inhibitors
  • Reverse Transcriptase Inhibitor
  • Reverse Transcriptase
  • Antibodies
  • Base Sequence
  • Replication


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3071

    file did exist - 2155

    2 - 1 - 51